Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
22 févr. 2021 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
17 févr. 2021 07h30 HE
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
11 févr. 2021 16h17 HE
|
Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
30 nov. 2020 07h30 HE
|
Otonomy, Inc.
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13 juil. 2020 16h01 HE
|
Otonomy, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Pricing of $60.1 Million Public Offering
09 juil. 2020 09h00 HE
|
Otonomy, Inc.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Proposed Public Offering
08 juil. 2020 16h03 HE
|
Otonomy, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
06 juil. 2020 16h04 HE
|
Otonomy, Inc.
OTO-313 demonstrated a higher proportion of responders than placeboGiven clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitusOTO-313...
Otonomy Provides Business Update Related to COVID-19 Pandemic
09 avr. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a...
Otonomy Provides Corporate and Product Pipeline Update
09 janv. 2020 07h30 HE
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...